Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisaftoclax (APG-2575) Monotherapy or Combo in Advanced Solid Tumors and Breast Cancer
NCT04946864Phase 2Suspended
- Sponsor
- Ascentage Pharma
- Start
- Aug 2021
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of lisaftoclax in solid tumor and breast cancer (2 arms), sponsored by Ascentage Pharma. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Aug 2021; status: suspended.
02
Drugs
lisaftoclax
03
Conditions
solid tumorbreast cancer
Beyond the preview
Go deeper on NCT04946864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04946864.